Chiusura precedente | 0,1300 |
Aperto | N/D |
Denaro | 0,0000 |
Lettera | 0,0000 |
Prezzo d'esercizio | 15,00 |
Scadenza | 2024-05-17 |
Min-Max giorno | 0,1300 - 0,1300 |
Contratto - Min-Max | N/D |
Volume | |
Open Interest | N/D |
On track to present initial data from Phase 1/2 clinical trial of MRT-2359 for MYC-driven solid tumors in the second half of 2023Received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) for MRT-2359 for the treatment of small cell lung cancer (SCLC)Announced development candidate MRT-6160, a novel, highly selective molecular glue degrader of VAV1, with IND submission expected 1H 2024Strong cash position expected to sustain operations into 2025 and enable advancement of p
BOSTON, July 26, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a clinical stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the appointment of Anthony M. Manning, Ph.D., to its Board of Directors. Dr. Manning is a highly accomplished drug discovery leader in the field of autoimmune and inflammatory diseases. ”Dr. Manning brings extensive knowledge and experience in the field of immunology and inflammation to our B
BOSTON, May 30, 2023 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company is scheduled to present at the following investor and industry events in June: BIO International Healthcare Conference in Boston; panel entitled “From Serendipity to Rational Design, Redefining the Rules of Molecular Glue Discovery” on June 5 at 1PM ET in Session Room 208Jefferies